Last reviewed · How we verify
NCT06572683: R01RF
Resonant Frequency rTMS: A Novel Approach to Target Circuit Modulation in Major Depressive Disorder
NA trial testing Transcranial Magnetic Stimulation in MDD in 84 participants. Enrolling by invitation.
31 October 2028
Quick facts
| Lead sponsor | University of California, Los Angeles |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 84 |
| Start date | 12 February 2024 |
| Primary completion | 31 October 2028 |
| Estimated completion | 31 October 2028 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Transcranial Magnetic Stimulation — full drug profile →
Conditions studied
- MDD — all drugs for MDD →
- Depression — all drugs for Depression →
Sponsor
University of California, Los Angeles
Who can join
Adults 21 to 75, any sex, with MDD or Depression. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the study is to develop a more personalized brain stimulation using repetitive transcranial magnetic stimulation or rTMS approach to treat major depressive disorder (MDD). The investigators had previously developed a personalized rTMS treatment by examining the effectiveness of different rTMS frequency from 5 to 18 Hertz (Hz). The optimal treatment frequency is termed resonance frequency and varies across individuals. There has not been a systematic method to identify the best stimulation frequency in an individual-specific way. In this project, the investigators will identify and compare 3 rTMS frequencies, all targeting the brain region called left dorsolateral prefrontal cortex (DLPFC): 1 that engages brain circuit connectivity the most- the investigators call this resonant frequency (RF)-max (RF-max), 1 that is the lowest ranked resonance frequency called RF-min and 1 that is standard of care treatment - rTMS of 10 Hz as a point of comparison. This study is a multi-sites project that will be conducted at UCLA and Butler hospital. This study will enroll 84 participants with MDD over the course of 4.5 years. Participants will undergo a brain imaging scan or magnetic resonance imaging (MRI), 3 electroencephalograms (or EEG, a measurement of electrical activity of the brain), to identify rTMS resonance frequencies (RFs), 3 sessions of different resonant frequencies of rTMS in combination with EEG, totaling up to 7 in person visits. Participation will take up to 4 weeks.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06572683
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Transcranial Magnetic Stimulation
Trials testing the same drug.
- NCT07526285 — Personalized Repetitive Transcranial Magnetic Stimulation (PrTMS) for Treatment of Post-Traumatic Stress Disorder (PTSD) · NA · not yet recruiting
- NCT07050862 — rTMS for Tobacco Use in Veterans · NA · not yet recruiting
- NCT07145866 — Varenicline and Accelerated Transcranial Magnetic Stimulation (TMS) for Quitting Nicotine Use (Pilot Study) · Phase 4 · not yet recruiting
- NCT07516028 — Brain Connectivity and Corticospinal Excitability in Response to Moderate Hypoxia · NA · not yet recruiting
- NCT07389694 — Using Transcranial Magnetic Stimulation to Treat Stuttering · NA · recruiting
Other recruiting trials for MDD
Currently open trials in the same condition.
- NCT07422844 — Dynamic Network Response to TMS Treatment · recruiting
- NCT07111390 — Feasibility of Home-Based Intermittent 60Hz Light Therapy for Major Depressive Disorder (MDD) · NA · recruiting
- NCT06828887 — Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD · Phase 2 · recruiting
- NCT06132178 — Psilocybin rTMS for Treatment Resistant Depression · Phase 2 · recruiting
- NCT07269964 — At-Home tDCS as Maintenance Therapy · NA · recruiting
Other University of California, Los Angeles trials
Trials by the same sponsor.
- NCT04846517 — rTMS for Aneroxia Nervosa in Youth · NA · not yet recruiting
- NCT06701760 — Sodium Lactate in Severe TBI · Phase 2 · not yet recruiting
- NCT04996667 — Effect of iNO in Patients With Submassive and Massive PE · Phase 2 · withdrawn
- NCT05067387 — Evaluation of Oral THC and CBD in Men and Women · Phase 1 · not yet recruiting
- NCT07534696 — Evaluation of Non-Invasive Pelvic Floor Neuromuscular Stimulation for Urinary Incontinence After Prostatectomy · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06572683 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of California, Los Angeles
- Last refreshed: 22 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06572683.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing